NASDAQ:IMNP - Immune Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.1931 -0.02 (-9.39 %)
(As of 06/21/2018 04:00 PM ET)
Previous Close$0.2111
Today's Range$0.1870 - $0.2198
52-Week Range$0.19 - $3.43
Volume791,557 shs
Average Volume1.10 million shs
Market Capitalization$6.78 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58
Immune Pharmaceuticals logoImmune Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops therapeutic agents in the fields of immuno-inflammation, dermatology, and immuno-oncology. The company's lead product candidate is bertilimumab, a clinical-stage human antibody, which is in Phase II clinical trial that targets eotaxin-1 for the treatment of bullous pemphigoid, crohn's, and ulcerative colitis diseases. It also develops NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, which is in preclinical stage for the treatment of atopic dermatitis and psoriasis. The company's immuno-oncology pipeline includes Ceplene for the maintenance of remission in patients with acute myeloid leukemia, which is in Phase III clinical trial in the United States and has approved in European Union; Crolibulin, a small molecule vascular disrupting agents (VDA) and apoptosis inducer that is in Phase II clinical trial for the treatment of patients with solid tumors; Azixa, a Phase II microtubular destabilizer that functions as a VDA; NanomAbs, a preclinical stage antibody-drug conjugate platform that allows the targeted delivery of combinations of chemotherapeutics into cancer cells; and bispecific antibodies, which are in preclinical stage against immune-oncology targets. In addition, it develops AmiKet, a prescription topical analgesic cream that has completed II clinical trials for the treatment of neuropathic pain; and LidoPAIN, an adhesive-backed, lidocaine-based patch that is in Phase II clinical trial for the treatment of acute lower back pain. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.

Receive IMNP News and Ratings via Email

Sign-up to receive the latest news and ratings for IMNP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IMNP
CUSIPN/A
Phone201-464-2677

Debt

Debt-to-Equity Ratio0.15
Current Ratio0.31
Quick Ratio0.31

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book0.30

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-17,880,000.00
Net MarginsN/A
Return on Equity-248.29%
Return on Assets-59.87%

Miscellaneous

Employees7
Outstanding Shares32,000,000

Immune Pharmaceuticals (NASDAQ:IMNP) Frequently Asked Questions

What is Immune Pharmaceuticals' stock symbol?

Immune Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMNP."

How were Immune Pharmaceuticals' earnings last quarter?

Immune Pharmaceuticals Inc (NASDAQ:IMNP) issued its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.05. View Immune Pharmaceuticals' Earnings History.

When is Immune Pharmaceuticals' next earnings date?

Immune Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 20th 2018. View Earnings Estimates for Immune Pharmaceuticals.

What price target have analysts set for IMNP?

1 brokerages have issued 12-month price objectives for Immune Pharmaceuticals' stock. Their forecasts range from $2.00 to $2.00. On average, they expect Immune Pharmaceuticals' share price to reach $2.00 in the next twelve months. View Analyst Ratings for Immune Pharmaceuticals.

Who are some of Immune Pharmaceuticals' key competitors?

Who are Immune Pharmaceuticals' key executives?

Immune Pharmaceuticals' management team includes the folowing people:
  • Dr. Elliot M. Maza J.D., MBA, CPA, Pres, CEO, Principal Financial Officer, Principal Accounting Officer, Sec. & Director (Age 62)
  • Dr. Anthony S. Fiorino, Chief Medical Officer & COO (Age 51)
  • Mr. Christine J. Petraglia, Director of Investor Relations
  • Ms. Anna Baran-Djokovic J.D., Director of Corp. Affairs
  • Dr. Miri Ben-Ami, Pres of Immune Oncology Pharmaceuticals Inc

Has Immune Pharmaceuticals been receiving favorable news coverage?

Media coverage about IMNP stock has trended somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Immune Pharmaceuticals earned a media sentiment score of 0.16 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 46.73 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Immune Pharmaceuticals?

Shares of IMNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immune Pharmaceuticals' stock price today?

One share of IMNP stock can currently be purchased for approximately $0.1931.

How big of a company is Immune Pharmaceuticals?

Immune Pharmaceuticals has a market capitalization of $6.78 million. Immune Pharmaceuticals employs 7 workers across the globe.

How can I contact Immune Pharmaceuticals?

Immune Pharmaceuticals' mailing address is 550 Sylvan Avenue, Englewood Cliffs NJ, 07632. The biopharmaceutical company can be reached via phone at 201-464-2677 or via email at [email protected]


MarketBeat Community Rating for Immune Pharmaceuticals (IMNP)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  245
MarketBeat's community ratings are surveys of what our community members think about Immune Pharmaceuticals and other stocks. Vote "Outperform" if you believe IMNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.